Clinical Trial Update: Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is investigating the combination of Erdafitinib and Enfortumab Vedotin for metastatic bladder/urothelial cancers after prior chemothera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Renal Pelvis Cancer
• Ureteral Cancer
• Urethral Cancer
• Urothelial Carcinoma

Drugs mentioned

• BALVERSA (erdafitinib)
• Padcev (enfortumab vedotin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING